Idarucizumab (Praxbind)
Revision as of 05:47, 19 October 2015 by PeterYang (talk | contribs) (PeterYang moved page Idarucizumab to Idarucizumab (Praxbind): FDA approval)
Mechanism of action
A monoclonal antibody fragment that binds Dabigatran (Pradaxa) with very high affinity. In clinical trials it completely reverses the effect of dabigatran within minutes.
Preliminary data
- Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-520. Epub 2015 Jun 22. link to original article PubMed